1. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2017. Available at:
http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/
. Last accessed 3 January 2017.
2. Price D, Jones R, Gruffyd-Jones K, Brusselle G, Miravitlles M, Baldwin M, et al. Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: an analysis of UK patient dataset. Eur Respir J 2014;44(Suppl. 58):P2422 (Abstract).
3. White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP. Overtreatment of COPD with inhaled corticosteroids--implications for safety and costs: cross-sectional observational study. PLoS One. 2013;8:e75221.
4. Miravitlles M, Sicras A, Crespo C, Cuesta M, Brosa M, Galera J, et al. Costs of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care setting. Ther Adv Respir Dis. 2013;7:139–50.
5. Läkemedelverkets Medical Products Agency (Sweden): Läkemedelverkets expert panel. Farmakologisk behandling av kroniskt obstruktiv lungsjukdom (KOL) – behandlingsrekommendationer (In Swedish). 2009:Suppl 2:13–28. Available at:
https://lakemedelsverket.se/kol
.